Why this gap matters now
Antimicrobial resistance is no longer a future threat. More than a million deaths a year are directly attributable to it, and forecasts suggest 39 million more by 2050 (GBD 2021 Antimicrobial Resistance Collaborators, 2024). In 2024, world leaders committed to reduce deaths associated with AMR by 10% by 2030 (World Health Organization, 2024b), and in 2025 WHO reported that one in six laboratory-confirmed infections was resistant (World Health Organization, 2025).
Industry and research are both moving. A rapid urine test that names the right antibiotic in 45 minutes won the Longitude Prize in 2024 (Nesta, 2024), and Cochrane reviews show that biomarker tests can safely reduce prescribing (Smedemark et al., 2022). The missing piece is evidence from the settings with the highest burden, where test, clinic and patient realities differ sharply from those of the trials.
Why the gap persists
Most trials are run where laboratories, funding and research infrastructure already exist. The six randomised trials of rapid susceptibility testing were all in specialised centres in high-income countries (Anton-Vazquez et al., 2021). Meanwhile, WHO notes that capacity to diagnose bacterial infection remains very limited in many low- and middle-income countries (World Health Organization, 2024a).
- Accuracy studies are easier to run than impact trials, so many tests have evidence of accuracy but not of changed decisions or outcomes.
- Much antibiotic use happens outside formal clinics, where research access is harder.
- Supply chains, quality control and payment models for tests are rarely studied alongside clinical effect.
There is also a mismatch of outcomes. Device developers need accuracy data for approval, while health systems need to know whether a test changes what clinicians do, what it costs and whether patients recover as well. WHO has proposed tracking the share of people seeking care in facilities with access to quality-assured bacteriology (World Health Organization, 2024a), but the studies that would show how point-of-care testing contributes to that goal in first-level care are still few.
Is this feasible for a doctorate?
Yes, with a focused scope. A strong thesis might combine a systematic review, a pilot or feasibility cluster trial in a small number of clinics, and an economic and process evaluation. A full definitive trial is usually beyond one doctorate, but a well-run feasibility study is publishable and builds the case for funding.
| Consideration | What to plan for |
|---|---|
| Setting access | Agreements with clinics or pharmacies and local investigators from the start. |
| Ethics | Approval in each country, consent in local languages and plans for patients who test positive. |
| Test supply | Reliable kits, cold chain where needed, and quality assurance against a reference method. |
| Skills | Trial design, microbiology, health economics and qualitative methods across the supervisory team. |
| Outcomes | Prescribing, recovery and safety, not test accuracy alone. |
